Bayer has switched the focus of its AI-based research partnership with Recursion Pharmaceuticals from fibrosis to oncology, as part of a wider R&D re-think.
Bayer Switches Focus Of Recursion AI Pact To Oncology
After streamlining its R&D strategy in the summer, Bayer’s rewritten pact with Recursion Pharmaceuticals looks like a vote of confidence in its AI-enabled drug discovery platform.
